Katrina Wilcox Hagberg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3548144/publications.pdf

Version: 2024-02-01

		1305906	1637695	
10	199	8	9	
papers	citations	h-index	g-index	
10	10	10	288	
10	10	10	200	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Presence of Codes for Indication for Use in Clinical Practice Research Datalink Aurum: An Assessment of Benign Prostatic Hyperplasia Treatments. Clinical Epidemiology, 2022, Volume 14, 641-652.	1.5	2
2	Quality and Completeness of Myocardial Infarction Recording in Clinical Practice Research Datalink Aurum. Clinical Epidemiology, 2021, Volume 13, 745-753.	1.5	14
3	<scp>CPRD</scp> Aurum database: Assessment of data quality and completeness of three important comorbidities. Pharmacoepidemiology and Drug Safety, 2020, 29, 1456-1464.	0.9	31
4	Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis. Clinical Epidemiology, 2020, Volume 12, 153-161.	1.5	16
5	Quality and completeness of diagnoses recorded in the new <scp>CPRD</scp> Aurum Database: evaluation of pulmonary embolism. Pharmacoepidemiology and Drug Safety, 2020, 29, 1134-1140.	0.9	26
6	Maternal depression and antidepressant use during pregnancy and the risk of autism spectrum disorder in offspring. Clinical Epidemiology, 2018, Volume 10, 1599-1612.	1.5	38
7	Risk of Incident Antidepressantâ€Treated Depression Associated with Use of 5αâ€Reductase Inhibitors Compared with Use of αâ€Blockers in Men with Benign Prostatic Hyperplasia: A Populationâ€Based Study Using the Clinical Practice Research Datalink. Pharmacotherapy, 2017, 37, 517-527.	1.2	10
8	Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clinical Epidemiology, 2017, Volume 9, 83-91.	1.5	19
9	Validation of autism spectrum disorder diagnoses recorded in the Clinical Practice Research Datalink, 1990–2014. Clinical Epidemiology, 2017, Volume 9, 475-482.	1.5	14
10	Risk of erectile dysfunction associated with use of $5 \cdot \hat{l}_{\pm}$ reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ, The, 2016, 354, i4823.	3.0	29